tarlatamab (AMG 757)

Indications

• investigational agent for treatment of small cell lung carcinoma in patients previously treated with platinum-based regimen & anti PD-1)/PD-L1 antibodies

Dosage

• 0.003-100 mg IV presumptively by infusion every 2 weeks

Pharmacokinetics

• mean terminal elimination 1/2 life ia 5.7 days

Adverse effects

• cytokine release syndrome (52%)
• pyrexia in 43 patients (40%)
• constipation in 33 patients (31%)

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• novel bispecific T cell engagenovel bispecific T cell engager
• binds to delta-like ligand 3 (DLL3) on tumor cells & cluster of differentiation 3 (CD3) on T cells, triggering T cell-dependent antitumor immunity
• DLL3 is an inhibitory Notch ligand highly expressed in SCLC & other neuroendocrine tumors, but minimally expressed in normal tissues

Notes

• median progression-free survival: 3.7 months
• median overall survival: 13.2 months

More general terms

• antineoplastic monoclonal antibody